Press Releases
Global Alzheimer’s Platform Foundation® Applauds Neurologists for Speaking Out Against Proposed CMS Plan to Restrict Coverage to Alzheimer’s Patients
New survey finds that 83% of neurologists believe that the safety and efficacy of an entire class of drugs should not be determined by the results of one medication. Washington, D.C. (February 2, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of […]
STATEMENT: Global Alzheimer’s Platform Foundation® Applauds Biogen for 18 Percent Diversity Recruitment Goal for Participants in Aduhelm Confirmatory Trial
Washington, D.C. (January 27, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, applauded the announcement today by Biogen Inc. that it would ensure that at least 18 percent of participants in its FDA mandated study will […]
Global Alzheimer’s Platform Foundation® (GAP) Condemns CMS Preliminary Coverage Decision on First Disease Modifying Drug for Alzheimer’s as Repudiation of President’s Promise to Advance Treatments for Alzheimer’s for all Americans
GAP calls for a traditional National Coverage Determination for ADUHELM consistent with past CMS decisions which will ensure access and equity for all patients stricken with Alzheimer’s. Washington, D.C. (January 11, 2022) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for […]
Global Alzheimer’s Platform Foundation® Applauds Biogen for Reducing Cost of ADUHELM
GAP Renews Its Call for CMS to Cover the New Class of Drugs for the Treatment of Alzheimer’s Washington, D.C. (December 20, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation® (GAP), a person-centric non-profit organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on the […]
Atlanta Metro Communities Gain Access to Renowned Alzheimer’s Research Network Through Local Clinical Trial Site
iResearch Atlanta will join the Global Alzheimer’s Platform Foundation®’s network (GAP-Net) of clinical trial sites working to bring new treatments to those living with the disease and and improve equity in research. Contact: Peter Buonanno – [email protected] – 704.989.5501 WASHINGTON, D.C. (December 7, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) announced that iResearch Atlanta […]
Orlando Seniors Gain Access to Innovative Alzheimer’s Clinical Trial
Study leaders at new Global Alzheimer’s Network Site Commit to Improving Equity in Florida Alzheimer’s Research Contact: Peter Buonanno – [email protected] – 408-466-5952 Washington, DC (November 18, 2021) – With enrollment in full swing, the Global Alzheimer’s Platform Foundation® (GAP) has announced that K2 Medical Research will join both their GAP-Network of clinical trial sites […]
Global Alzheimer’s Platform Foundation (GAP) Taps Leading International Clinical Trial Expert for Senior Advisor Role
Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]
To Beat Alzheimer’s, Tampa Seniors From Underserved Communities can get Involved in Clinical Trials
GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]
Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) to Partner with the Global Alzheimer’s Platform Foundation® (GAP) and Other Industry Leaders on Breakthrough Alzheimer’s Study
Contact: Peter Buonanno – [email protected], 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]
Statement: Global Alzheimer’s Platform Foundation Praises FDA for Aducanumab Approval
Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]